Study ID: Merck MK-3475-199 Keynote 199
Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy
Bismarck Region, Fargo Region, Sioux Falls Region
Christopher Sumey, MD,Amit Panwalkar, MD,John Reynolds, MD
Active - Open to Accrual
For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.